LeadIQ logo
Learn more at LeadIQ.com
✕

Access Insights for Barinthus Biotherapeutics and Millions of Other Companies

Sign up for full access to Barinthus Biotherapeutics information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Insights

Recent Acquisitions Barinthus Biotherapeutics was acquired by Pfizer, Inc. in December 2022, indicating growth potential and expanded resources for the company.

Collaborations with Key Organizations The collaboration with the University of Oxford and Coalition for Epidemic Preparedness Innovations (CEPI) positions Barinthus Biotherapeutics as an innovative player in the vaccine development space, opening up opportunities for strategic partnerships.

Breakthrough Vaccine Launch The recent launch of VTP-300 by Barinthus Biotherapeutics demonstrates a commitment to product innovation and could attract interest from potential buyers seeking cutting-edge vaccine solutions.

Recognition in the Industry Being recognized as the Breakthrough Company of the Year at the 2022 BioBuzz Awards reflects positively on Barinthus Biotherapeutics' reputation and could attract attention from investors or collaborators looking to associate with an esteemed company.

Financial Stability and Funding With reported revenue between $10M - $50M and $168M in funding, Barinthus Biotherapeutics showcases financial stability that can instill confidence in potential partners or investors seeking long-term relationships.

Similar companies to Barinthus Biotherapeutics

✕

Access Insights for Barinthus Biotherapeutics and Millions of Other Companies

Sign up for full access to Barinthus Biotherapeutics information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Barinthus Biotherapeutics Tech Stack

Barinthus Biotherapeutics uses 8 technology products and services including Optimise, SAP, Revslider, and more. Explore Barinthus Biotherapeutics's tech stack below.

  • Optimise
    Affiliate Advertising Networks
  • SAP
    Customer Relationship Management
  • Revslider
    Miscellaneous
  • Acquia Cloud Platform
    Platform As A Service
  • Greenhouse
    Recruitment Marketing
  • Adobe Tag Manager
    Tag Management
  • Google Tag Manager for WordPress
    Web Platform Extensions
  • Contact Form 7
    Web Platform Extensions

Media & News

Barinthus Biotherapeutics's Email Address Formats

Barinthus Biotherapeutics uses at least 1 format(s):
Barinthus Biotherapeutics Email FormatsExamplePercentage
First.Last@vaccitech.co.ukJohn.Doe@vaccitech.co.uk
49%
First@vaccitech.co.ukJohn@vaccitech.co.uk
1%
First.Last@vaccitech.co.ukJohn.Doe@vaccitech.co.uk
49%
First@vaccitech.co.ukJohn@vaccitech.co.uk
1%

Frequently Asked Questions

Where is Barinthus Biotherapeutics's headquarters located?

Minus sign iconPlus sign iconBarinthus Biotherapeutics's main headquarters is located at Units 6-10 Zeus Building, Rutherford Avenue Harwell, Oxfordshire OX11 0DF GB. The company has employees across 4 continents, including EuropeNorth AmericaAfrica.

What is Barinthus Biotherapeutics's stock symbol?

Minus sign iconPlus sign iconBarinthus Biotherapeutics is a publicly traded company; the company's stock symbol is BRNS.

What is Barinthus Biotherapeutics's official website and social media links?

Minus sign iconPlus sign iconBarinthus Biotherapeutics's official website is vaccitech.co.uk and has social profiles on LinkedIn.

How much revenue does Barinthus Biotherapeutics generate?

Minus sign iconPlus sign icon As of October 2024, Barinthus Biotherapeutics's annual revenue reached $35M.

What is Barinthus Biotherapeutics's SIC code NAICS code?

Minus sign iconPlus sign iconBarinthus Biotherapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Barinthus Biotherapeutics have currently?

Minus sign iconPlus sign iconAs of October 2024, Barinthus Biotherapeutics has approximately 122 employees across 4 continents, including EuropeNorth AmericaAfrica. Key team members include Chief Scientific Officer: N. P.Chief Business Officer: G. G.Chief Financial Officer: G. B.. Explore Barinthus Biotherapeutics's employee directory with LeadIQ.

What industry does Barinthus Biotherapeutics belong to?

Minus sign iconPlus sign iconBarinthus Biotherapeutics operates in the Biotechnology Research industry.

What technology does Barinthus Biotherapeutics use?

Minus sign iconPlus sign iconBarinthus Biotherapeutics's tech stack includes OptimiseSAPRevsliderAcquia Cloud PlatformGreenhouseAdobe Tag ManagerGoogle Tag Manager for WordPressContact Form 7.

What is Barinthus Biotherapeutics's email format?

Minus sign iconPlus sign iconBarinthus Biotherapeutics's email format typically follows the pattern of . Find more Barinthus Biotherapeutics email formats with LeadIQ.

How much funding has Barinthus Biotherapeutics raised to date?

Minus sign iconPlus sign icon As of October 2024, Barinthus Biotherapeutics has raised $168M in funding. The last funding round occurred on Mar 17, 2021 for $168M.

When was Barinthus Biotherapeutics founded?

Minus sign iconPlus sign iconBarinthus Biotherapeutics was founded in 2016.
Barinthus Biotherapeutics

Barinthus Biotherapeutics

Biotechnology ResearchOxfordshire, United Kingdom51-200 Employees

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Biotherapeutics. With a broad pipeline, built around four proprietary platform technologies: ChAdOx, MVA, SNAP-TI, and SNAP-CI; Barinthus Biotherapeutics is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; and VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Biotherapeutics’ proven scientific expertise, diverse portfolio and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity and cancers that have a significant impact on their everyday lives.

✕

Access Insights for Barinthus Biotherapeutics and Millions of Other Companies

Sign up for full access to Barinthus Biotherapeutics information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Section iconCompany Overview

Headquarters
Units 6-10 Zeus Building, Rutherford Avenue Harwell, Oxfordshire OX11 0DF GB
Website
vaccitech.co.uk
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
BRNS
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $168M

    Barinthus Biotherapeutics has raised a total of $168M of funding over 5 rounds. Their latest funding round was raised on Mar 17, 2021 in the amount of $168M.

  • $10M$50M

    Barinthus Biotherapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $168M

    Barinthus Biotherapeutics has raised a total of $168M of funding over 5 rounds. Their latest funding round was raised on Mar 17, 2021 in the amount of $168M.

  • $10M$50M

    Barinthus Biotherapeutics's revenue is in the range of $10M$50M

Company Leadership

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

✕

Access Insights for Barinthus Biotherapeutics and Millions of Other Companies

Sign up for full access to Barinthus Biotherapeutics information. No credit card needed.
OR
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.